The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index; 77 of the 205 sources its claims cite were checked for support.
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Open accessAbstract
Inflammation is a hallmark and potent driver of pathological vascular remodelling in atherosclerosis. However, current anti-inflammatory therapeutic strategies have shown mixed results. As an alternative perspective on the conundrum of chronic inflammation emerging evidence points towards a small subset of senescent cells as a critical player and central node driving atherosclerosis. Senescent cells belonging to various cell types are a dominant and chronic source of a large array of pro-inflammatory cytokines and various additional plaque destabilizing factors, being involved with various aspects of atherosclerosis pathogenesis. Antagonizing these key agitators of local chronic inflammation and plaque instability may provide a causative and multi-purpose therapeutic strategy to treat atherosclerosis. Anti-senescence treatment options with translational potential are currently in development. However, several questions and challenges remain to be addressed before these novel treatment approaches may enter the clinical setting.
Overview
CoChat Summary
TL;DR
This review argues that senescent cells and their senescence-associated secretory phenotype (SASP) are upstream, chronic drivers of inflammation and plaque destabilization in atherosclerosis. It synthesizes experimental and clinical evidence and discusses anti-senescence therapeutic strategies, while highlighting unresolved challenges before clinical translation.
Key findings
- Senescent endothelial cells, vascular smooth muscle cells (VSMCs), macrophages/foam cells, monocytes, fibroblasts, and T cells accumulate in atherosclerotic arteries and secrete SASP factors including IL-1α, IL-1β, IL-6, IL-8, IL-18, TNF-α, and multiple MMPs, promoting plaque inflammation, cap thinning, calcification, erosion, and intra-plaque angiogenesis.
- Clinical evidence links senescence to atherosclerosis: 57.1% of men and 68.7% of women older than 70 have atherosclerotic lesions, rising to 87.4% of men and 88.9% of women older than 85; only 11.9% and 40.3% of the age effect in men and women, respectively, is attributable to longer exposure to classical risk factors. In Hutchinson–Gilford progeria, myocardial infarction or stroke occurs at a mean age of 13 years without classical risk factors, and senescent VSMCs accounted for 18% of all plaque cells in human carotid atherosclerosis.
- Anti-senescence strategies with translational potential include senolytics (e.g., navitoclax, dasatinib plus quercetin), SASP inhibition (e.g., NLRP3, cGAS-STING, JAK, TRAF6, p38 MAPK), energy-sensing pathway modulation (mTOR, SIRT-1, FOXO3, AMPK), epigenetic modulation, and cellular reprogramming; several existing cardiovascular drugs also have anti-senescent effects.
- The paper identifies key challenges: lack of specific senescence markers, paradoxical pro-atherosclerotic effects of some cell cycle inhibitor knockouts, potential interference with beneficial acute senescence roles, senolytic adverse effects, and the need for better biomarkers and imaging to select patients and track therapy.
Methods
- Narrative review; no primary data collection or systematic quantitative synthesis.
- Synthesizes experimental and clinical literature on cellular senescence, SASP, atherosclerosis pathogenesis, and anti-senescence therapies, including preclinical models (e.g., INK-ATTACK, p16-3MR, LDL receptor-knockout mice) and clinical trials/studies (e.g., CANTOS, CIRT, MILES, TAME, idiopathic pulmonary fibrosis senolytic trial).
- Main analysis is conceptual and mechanistic, organized around cell-specific senescence effects, clinical evidence, therapeutic targets, and future directions.
Limitations
- The paper states that senescent cell detection is hampered by lack of specific markers; senescence-associated β-galactosidase staining and p16 INK4a expression can yield false-positive results in macrophages, and better understanding of senescence in vascular disease development is needed.
- It notes that patient selection for anti-senescence trials is challenging because senescence also limits myocardial and liver fibrosis, promotes skin healing, and contributes to embryonal development; oncogenesis risk and the need for senescence-specific biomarkers/imaging remain unresolved.
- Evident from the text: as a narrative review, it does not provide a systematic search strategy, quantitative synthesis, or new primary data, and many proposed mechanisms and therapies remain preclinical or speculative.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
30 Valid · 4 Not valid · 73 Not checked · 22 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intriguingly, cellular senescence and atherosclerosis share multiple causative stimuli1,11,12: oxidized and electronegative low-density lipoprotein (LDL),13,14 inflammation,15 reactive oxygen species,8 cigarette smoke,16 hypertension,17 hyperglycaemia,18 cytomegalovirus (CMV) infection,19 telomere attrition,20 mitochondrial failure,21 dysfunctional autophagy,22 and genomic damage.8”
§ Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis > Introduction
What the sources say
- Partly supportedcites [1] Libby, 2009, Inflammation in atherosclerosis: from pathophysiology to practice, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The Abstract and “Innate immunity in atherosclerosis” section link inflammatory mechanisms and modified lipoproteins to atherosclerosis. Our copy does not address cellular senescence or establish that it and atherosclerosis share causative stimuli. (LLM, conf=0.79)
- Supportedcites [11] Shah, 2018, Defective base excision repair of oxidative DNA damage in vascular smooth muscle cells promotes atherosclerosis, Circulation source
The Results (page unavailable) report that oxidative DNA damage at telomeres induces VSMC senescence, while the Discussion (page unavailable) says oxidative DNA damage promotes plaque development. The paper also identifies reactive oxygen species as a source of that damage. These passages support the introductory claim that senescence and atherosclerosis share multiple causative stimuli; the separately cited items in the sentence’s list are not all attributed to this source. (LLM, conf=0.86)
- Supportedcites [12] Grootaert, 2018, Defective autophagy in atherosclerosis: to die or to senesce?, Oxid Med Cell Longev source
The Introduction identifies smoking, hypertension and diabetes among atherosclerosis risk factors, while Section 2 describes oxidative stress and oxidized lipids in atherosclerotic plaques. Sections 3 and 5 link defective autophagy and oxidative stress to cellular senescence. Together, these passages support the cited general claim that the two share multiple contributing stimuli; the individual items in the sentence have separate citations. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Strategies to target upstream effectors in the inflammatory signalling cascade may provide a solution for these issues.5”
§ Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis > Introduction
What the sources say
- Supportedcites [5] Ridker, 2016, From CRP to IL-6 to IL-1: moving upstream to identify novel targets for atheroprotection, Circ Res source
The Abstract states that 'moving upstream in the inflammatory cascade from CRP to IL-6 to IL-1 provides novel therapeutic opportunities for atheroprotection,' and the Introduction that clinical investigation moved upstream 'seeking more promising targets for anti-inflammatory atheroprotection' because CRP 'is unlikely to provide an effective target for intervention.' The IL-6 section adds that 'moving further upstream beyond IL-6 may be needed for anti-inflammatory approaches to atheroprotection,' addressing the limitations of downstream targeting. The citing sentence is hedged ('may provide a solution'), so the source's stronger assertion supports it. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: unclear — It is unclear whether it could be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, CD4+, CD28-null, CD45 re-expressing senescent T-cells (also known as CD4+ T-EMRA cells) were found to be highly active subpopulations, expressing increased amounts of TNF-α, INF-γ, CXCR-3 (C-X-C chemokine receptor), CCR-6, CCR-7 (C-C motif chemokine receptor 6 and 7), and the anti-apoptotic Bcl-2 family proteins.19,116”
§ Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis > Evidence on the cellular level of the contribution of senescence to atherosclerosis
What the sources say
- Partly supportedcites [19] Broadley, 2017, Expansions of cytotoxic CD4(+)CD28(-) T cells drive excess cardiovascular mortality in rheumatoid arthritis and other chronic inflammatory conditions and are triggered by CMV infection, Front Immunol sourceExperimental — accuracy not yet measured
The section “CD4+CD28− T Cells are Terminally Differentiated Effector Cells” (page not supplied) reports greater TNF-α and IFN-γ production, cytotoxicity, expression of CXCR3, CCR6 and CCR7, and resistance to apoptosis. It does not identify increased Bcl-2 family protein expression. The CMV section defines TEMRA as CD45RA-reexpressing cells but only hypothesizes that CD28− cells arise from TEMRA as well as TEM, rather than equating all CD28− cells with TEMRA. (LLM, conf=0.89)
- Partly supportedcites [116] Bullenkamp, 2016, Targeting T cells to treat atherosclerosis: odyssey from bench to bedside, Eur Heart J Cardiovasc Pharmacother sourceExperimental — accuracy not yet measured
The “CD4+CD28null T cells” section says these cells secrete more IFN-γ and TNF-α than conventional CD28+ T cells and reports increased anti-apoptotic Bcl-2 in rheumatoid arthritis. It does not identify CD28-null cells as CD45 re-expressing T-EMRA cells or report increased CXCR3, CCR6, or CCR7; its discussion of Bcl-2 is also specific to rheumatoid arthritis. Page numbers were not available in our copy. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, cancer therapies that induce cellular senescence, such as cisplatin, doxorubicin and radiation,129 accelerate atherosclerosis.130”
§ Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis > Clinical evidence linking ageing and senescence processes to atherosclerosis
What the sources say
- Partly supportedcites [129] Ghebre, 2016, Vascular aging: implications for cardiovascular disease and therapy, Transl Med (Sunnyvale) sourceExperimental — accuracy not yet measured
The section “Is vascular senescence a risk factor for cardiovascular disease?” (page unavailable) says doxorubicin, cisplatin, and radiation can induce senescence, and associates cancer treatments with vascular damage. It also links senescent endothelium to atherosclerosis, but does not state that these therapies accelerate atherosclerosis specifically. (LLM, conf=0.84)
- Partly supportedcites [130] Parry, 2016, Old cells, new tricks: chromatin structure in senescence, Mamm Genome sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says cytotoxic or genotoxic drugs can trigger cellular senescence, supporting the general point attached to citation 129. It does not identify cisplatin, doxorubicin, or radiation as examples. The claim that therapies accelerate atherosclerosis is attached to citation 130, not this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In clinical practice, the capability of cellular senescence to drive atherosclerosis independently of chronological ageing and classical risk factor exposure is seen in drastic examples of human progeria syndromes, such as Hutchinson–Gilford progeria (HGS), Werner syndrome, and other laminopathies.”
§ Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis > Clinical evidence linking ageing and senescence processes to atherosclerosis
What the sources say
- Partly supportedcites [101] Hamczyk, 2018, Vascular smooth muscle-specific progerin expression accelerates atherosclerosis and death in a mouse model of Hutchinson-Gilford progeria syndrome, Circulation sourceExperimental — accuracy not yet measured
The Clinical Implications section (page unavailable) says that children with Hutchinson–Gilford progeria develop generalized atherosclerosis and die prematurely from its complications. The Discussion (page unavailable) reports that vascular smooth muscle-specific progerin expression accelerates atherosclerosis in mice, but does not establish cellular senescence as the mechanism or independence from classical risk factors in humans. The paper does not address Werner syndrome or other laminopathies as examples of this claim. (LLM, conf=0.86)
- Partly supportedcites [126] Capell, 2007, Mechanisms of cardiovascular disease in accelerated aging syndromes, Circ Res sourceExperimental — accuracy not yet measured
The paper’s discussion of HGPS describes severe premature cardiovascular disease, and its Conclusions link cellular senescence to premature cardiovascular disease in HGPS and Werner syndrome. But it says these mechanisms ‘likely contribute’ rather than establishing that senescence drives atherosclerosis independently of classical risk factors. Its discussion of the HGPS vascular phenotype also notes that characteristic inflammatory and lipid features of atherosclerotic plaque were absent. (LLM, conf=0.87)
- Partly supportedcites [127] Wang, 2012, Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence, Circ Res sourceExperimental — accuracy not yet measured
The “Pathology of Normal and Premature Vascular Aging” section describes advanced atherosclerotic lesions in young patients with Hutchinson–Gilford progeria and accelerated atherosclerosis in Werner syndrome. It does not establish that cellular senescence drives these lesions independently of classical risk factors; it says metabolic effects also contribute in Werner syndrome. Page numbers were not available in our copy. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
62 more claims · 12 with their cited sources checked
Create a free account to see all 129 claims and to verify the 128 references still open.
- It may state two separate claims as one. 55
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This profile is indicative of an early cellular senescence phenotype62–66.”
From An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging (2021) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, senescence occurs at sites of atherosclerotic plaques, where it participates in multiple stages of atherogenesis (16, 39) and, through a paracrine SASP mechanism, accelerates the atherosclerotic process.”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis > Clinical evidence linking ageing and senescence processes to atherosclerosis
“Silencing of DMNT3a reportedly activated senescence in cancer and skin experimental models.140,141”
§ Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis > References
“141. Xie HF, Liu YZ, Du R, Wang B, Chen MT, Zhang YY, Deng ZL, Li J. miR-377 induces senescence in human skin fibroblasts by targeting DNA methyltransferase 1.”
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 1×
“Alternatively, the drugs could be applied periodically, with long offdrug periods.(175)”
BackgroundMechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391
Cellular senescence in aging and age-related disease: from mechanisms to therapy
Childs, B. G., Durik, M., Baker, D. J., & van Deursen, J. M. (2015) · Nature Medicine · doi:10.1038/nm.4000 · Cited by 2,363
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Self-citation
Research works printed but not linked: 2
- Prattichizzo, 2016, Aging (Albany NY), 3159
- Lakatta, 2015, J Mol Cell Cardiol, 1
Cited by
Sayed, N., Huang, Y., Nguyen, K., Krejciova-Rajaniemi, Z., Grawe, A. P., Gao, T., Tibshirani, R., Hastie, T., Alpert, A., Cui, L., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00082-y · Cited by 572
Strategies for targeting senescent cells in human disease
Gasek, N. S., Kuchel, G. A., Kirkland, J. L., & Xu, M. (2021) · Nature Aging · doi:10.1038/s43587-021-00121-8 · Cited by 501
Meftahi, G. H., Jangravi, Z., Sahraei, H., & Bahari, Z. (2020) · Inflammation Research · doi:10.1007/s00011-020-01372-8 · Cited by 289
“Additionally, senescent cells can release pro-inflammatory cytokines, including IL-1α, IL-1β, IL-6, IL-8, IL-18, CCL2, TNF-α, granulocyte macrophages colony-stimulating factor (GM-CSF), growth regulated oncogene (GRO), monocyte chemotactic protein (MCP)-2, MCP-3, MMP-1, MMP-3 [70, 71].”
BackgroundLagoumtzi, S. M., & Chondrogianni, N. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.003 · Cited by 279
Düsing, P., Zietzer, A., Goody, P. R., Hosen, M. R., Kurts, C., Nickenig, G., & Jansen, F. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02037-7 · Cited by 224
Metadata
- Authors
- Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Thum, Thomas
- Sedding, Daniel G
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-03
- Volume
- 41
- Issue
- 31
- Pages
- 2983-2996
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC7453834
- OpenAlex
- W2998051599
- Cited by
- 188
- References
- 209
- Citations by year
- 2026: 23 · 2025: 31 · 2024: 26 · 2023: 27 · 2022: 33 · 2021: 35 · 2020: 12
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (KFO FOR311-2, TH903/20-1)
- Cluster of Excellence REBIRTH
- Regenerative Biology to Reconstructive Therapy EXC 62
- German Academic Exchange Service Graduate School Scholarship Programme (57320205)
- Foundation Leducq
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- senescence-associated inflammation, cellular senescence, atherosclerosis, chronic inflammation, inflammatory cytokines, plaque vulnerability, vascular remodeling, anti-senescence therapy, atherosclerotic plaque
- MeSH terms
- Humans, Inflammation, Cytokines, Cellular Senescence, Atherosclerosis, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. https://app.cochat.ai/papers/10.1093/eurheartj/ehz919
- The paper
- Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020). Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz919
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.